Q-omics provides the consensus-scored BCL2L12 profile across patient tissues and cancer cell-line models. BCL2L12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BCL2L12 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, BCL2L12 RNA expression shows 19,543 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where BCL2L12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL2L12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL2L12 survival associations across molecular data types. BCL2L12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL2L12 RNA expression–survival associations across cancer types. High BCL2L12 expression shows unfavorable associations in ACC, KIRC, MESO, KIRP, LIHC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BCL2L12 RNA expression.
This table summarizes BCL2L12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for BCL2L12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL2L12 shows higher tumor expression in COAD, HNSC, BLCA, LIHC, LUAD and LUSC. The COAD box plot shows higher BCL2L12 RNA expression in tumor versus normal tissue (log2 FC = +1.472, t-test p < 0.001).
This table shows molecular features associated with BCL2L12 in patient tissues and cancer cell lines. In patient samples, BCL2L12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL2L12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
